Flexible partnership models

We believe that partnership provides highest likelihood of success in drug development – in particular for next-generation disruptive biotherapeutics or biotherapeutic tools. As discovery partner, we offer our deep expertise and innovative power in drug discovery and protein engineering via flexible partnering models. Joint project teams work closely together following the science – synergizing expertise.

“Alone we can do so little; together we can do so much.”
Helen Keller

Athebio is active in four dynamic fields:

T-cell Receptor Mimetics (TCRms)

Therapeutic area: Immuno-oncology
Approach: Directing immune cells precisely to kill tumor cells that display specific pHLAx markers
Partner: 3T Biosciences

Targeted Radio Therapy (tRT)

Therapeutic area: Radio-oncology
Approach: Directing therapeutic radio-nuclides precisely to kill tumor cells that display specific markers
Partner: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company

Adeno-associated Viruses (AAVs)

Therapeutic area: Viral gene therapy, e.g., applied in neurology and ophthalmology
Approach: Directing AAVs to tissue of interest to deliver therapeutic DNA
Partner: Regenxbio

Lipid Nanoparticles (LNPs)

Therapeutic area: Non-viral gene therapy, e.g., applied in oncology or infectious diseases (cf. COVID19)
Approach: Directing LNPs to any tissue of interest to deliver therapeutic mRNA
Partner: Acuitas Therapeutics

What is your project?

We are looking forward to hearing your ideas how Athebody® DARPins can enable your projects and how you like to access it.